bs_bs_banner
Original article
Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood C. RAE, MSC, Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, and Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, W. FURLONG, MSC, Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, and Health Utilities Inc, Dundas, Ontario, Canada, M. JANKOVIC, MD, Department of Pediatrics, Azienda Ospedaliera, S. Gerardo, Monza, Milan, Italy, ALBERT MOGHRABI, MD, Hôspital Ste. Justine, Montreal, Quebec, A. NAQVI, MD, The Hospital for Sick Children, Toronto, Ontario, Canada, A. SALA, MD, PHD, Department of Pediatrics, Azienda Ospedaliera, S. Gerardo, Monza, Milan, Italy, Y. SAMSON, MD, Le Centre Hospitalier de L’ Université Laval, Quebec City, Quebec, S. DEPAUW, MESC, Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, and Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, D. FEENY, PHD, Health Utilities Inc, Dundas, Ontario, and Department of Economics, University of Alberta, Edmonton, Alberta, & R. BARR, MBCHB, MD, Departments of Pediatrics, Pathology and Medicine, McMaster University, Hamilton, Ontario, Canada RAE C., FURLONG W., JANKOVIC M., MOGHRABI A., NAQVI A., SALA A., SAMSON Y., DEPAUW S., FEENY D. & BARR R. (2014) European Journal of Cancer Care 23, 779–785 Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood Berlin-Frankfurt-Munster (BFM) and Dana-Farber Cancer Institute (DFCI) consortia’s treatment strategies for acute lymphoblastic leukaemia (ALL) in children are widely used. We compared the health effects and monetary costs of hospital treatments for these two strategies. Parents of children treated at seven centres in Canada, Italy and the USA completed health-related quality of life (HRQL) assessments during four active treatment phases and at 2 years after treatment. Mean HRQL scores were used to calculate quality-adjusted life years (QALYs) for a period of 5 years following diagnosis. Total costs of treatment were determined from variables in administrative databases in a universally accessible and publicly funded healthcare system. Valid HRQL assessments (n = 1200) were collected for 307 BFM and 317 DFCI patients, with costs measured for 66 BFM and 28 DFCI patients. QALYs per patient were